Pluri Inc. Logo

Pluri Inc.

PLUR | TA

Overview

Corporate Details

ISIN(s):
US72942G2030
LEI:
Country:
Israel
Address:
Park Building No. 5, 3508409 Haifa
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Pluri Inc., formerly Pluristem Therapeutics, is a biotechnology company that researches, develops, and manufactures cell-based products and therapeutics. The company specializes in its proprietary 3D cell-expansion technology platform, which is used to create solutions for commercial use aimed at improving human well-being and sustainability. Pluri develops products from placenta-based cells for applications across the medical and pharmaceutical industries, often in collaboration with research partners and academic institutions.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Pluri Inc.. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-07-03 22:43
Post-Annual General Meeting Information
Immediate Report
Hebrew (modern) 224.6 KB
2025-07-03 22:43
Foreign Filer Report
Immediate Report
English 36.5 KB
2025-07-02 01:15
Director's Dealing
Other Report or Announcement
English 267.8 KB
2025-07-02 01:15
Foreign Filer Report
Other Report or Announcement
English 36.4 KB
2025-05-28 21:57
Proxy Solicitation & Information Statement
mediate Report of Meeting to be held on June 30, 2025
English 1.4 MB
2025-05-28 21:57
Pre-Annual General Meeting Information
mediate Report of Meeting to be held on June 30, 2025
English 184.6 KB
2025-05-28 01:52
Annual Report
Materials for Annual Meeting - Annual Report for 30.06.2024
English 346.4 KB
2025-05-28 01:52
Foreign Filer Report
Materials for Annual Meeting - Annual Report for 30.06.2024
English 36.3 KB
2025-05-28 01:36
Proxy Solicitation & Information Statement
Immediate Report of Meeting to be held on June 30, 2025, proxy
English 1.4 MB
2025-05-28 01:36
Pre-Annual General Meeting Information
Immediate Report of Meeting to be held on June 30, 2025, proxy
English 161.1 KB
2025-05-27 17:56
Pre-Annual General Meeting Information
FORM 8K – Updated Regurding Annual Meeting Date
English 112.3 KB
2025-05-27 17:56
Foreign Filer Report
FORM 8K – Updated Regurding Annual Meeting Date
English 36.3 KB
2025-05-20 17:26
Major Shareholding Notification
Form 13D/A-Yaky Yanay
English 168.9 KB
2025-05-20 17:26
Foreign Filer Report
Form 13D/A-Yaky Yanay
English 36.2 KB
2025-05-15 16:02
Management Discussion and Analysis
Pluri CEO Issues Shareholder Letter
English 110.5 KB

Automate Your Workflow. Get a real-time feed of all Pluri Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Pluri Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Makes saliva-based diagnostics accessible for at-home & pro health & drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AGRONOMICS LIMITED Logo Isle of Man ANIC
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK